Total Payments
$68,114
2024 Payments
$2,029
Companies
39
Transactions
518
Medicare Patients
10,855
Medicare Billing
$1.0M
Payment Breakdown by Category
Other$43,150 (63.3%)
Food & Beverage$13,706 (20.1%)
Travel$7,386 (10.8%)
Consulting$3,150 (4.6%)
Education$722.32 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,150 | 18 | 63.3% |
| Food and Beverage | $13,706 | 461 | 20.1% |
| Travel and Lodging | $7,386 | 23 | 10.8% |
| Consulting Fee | $3,150 | 1 | 4.6% |
| Education | $722.32 | 15 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $56,003 | 152 | $0 (2024) |
| ABIOMED | $2,619 | 28 | $0 (2024) |
| Abbott Laboratories | $1,858 | 28 | $0 (2024) |
| Cardiovascular Systems Inc. | $1,279 | 4 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $856.31 | 54 | $0 (2024) |
| Astellas Pharma US Inc | $630.31 | 8 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $490.95 | 39 | $0 (2024) |
| Amgen Inc. | $474.91 | 25 | $0 (2024) |
| CVRx, Inc. | $416.81 | 9 | $0 (2024) |
| Merck Sharp & Dohme LLC | $395.36 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,029 | 51 | ABIOMED ($739.13) |
| 2023 | $5,666 | 74 | Novartis Pharmaceuticals Corporation ($4,015) |
| 2022 | $1,664 | 48 | ABIOMED ($580.42) |
| 2021 | $1,513 | 43 | Abbott Laboratories ($387.68) |
| 2020 | $614.76 | 28 | Astellas Pharma US Inc ($178.99) |
| 2019 | $1,353 | 70 | Novartis Pharmaceuticals Corporation ($375.16) |
| 2018 | $18,052 | 94 | Novartis Pharmaceuticals Corporation ($14,756) |
| 2017 | $37,222 | 110 | Novartis Pharmaceuticals Corporation ($36,158) |
All Payment Transactions
518 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $145.02 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $13.68 | General |
| Category: Cardiovascular | ||||||
| 11/14/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $21.49 | General |
| Category: Heart Failure and Hypertension | ||||||
| 11/13/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/12/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $133.22 | General |
| Category: Cardiac Rhythm Management | ||||||
| 11/06/2024 | ATRICURE, INC. | SYNERGY ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $25.70 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $8.04 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/22/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $21.06 | General |
| 10/22/2024 | ATRICURE, INC. | SYNERGY ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/17/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $12.78 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $19.26 | General |
| Category: Cardiovascular | ||||||
| 09/23/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $13.21 | General |
| Category: Cardiovascular | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $5.22 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/10/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $151.26 | General |
| Category: Cardiac Rhythm Management | ||||||
| 09/10/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Cardiac Rhythm Management | ||||||
| 08/28/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $138.41 | General |
| Category: Cardiac Rhythm Management | ||||||
| 08/22/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $107.95 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/15/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/14/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/04/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $82.22 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/30/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $27.18 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 2,201 | 2,920 | $825,729 | $199,465 |
| 2022 | 23 | 1,982 | 2,718 | $794,133 | $188,935 |
| 2021 | 33 | 3,172 | 4,510 | $1.0M | $322,963 |
| 2020 | 34 | 3,500 | 5,408 | $932,219 | $335,603 |
Total Patients
10,855
Total Services
15,556
Medicare Billing
$1.0M
Procedure Codes
121
All Medicare Procedures & Services
121 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 428 | 586 | $223,442 | $51,101 | 22.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 213 | 222 | $127,155 | $30,217 | 23.8% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 151 | 153 | $85,373 | $20,432 | 23.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 43 | 43 | $54,486 | $13,819 | 25.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 78 | 81 | $42,476 | $11,038 | 26.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 66 | 115 | $41,335 | $10,827 | 26.2% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 42 | 83 | $28,422 | $7,312 | 25.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 499 | 682 | $29,964 | $7,027 | 23.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 115 | 117 | $24,351 | $6,229 | 25.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $25,476 | $6,210 | 24.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 70 | 98 | $23,394 | $6,159 | 26.3% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 25 | 25 | $22,581 | $5,023 | 22.2% |
| 93241 | Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 23 | 25 | $18,981 | $4,780 | 25.2% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 26 | 104 | $19,079 | $4,694 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 56 | $15,120 | $3,832 | 25.3% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 47 | 47 | $9,756 | $2,283 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 12 | $6,394 | $1,555 | 24.3% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 41 | 70 | $6,288 | $1,509 | 24.0% |
| 92978 | Ultrasound evaluation of heart blood vessel or graft with review by radiologist, initial vessel | Facility | 2023 | 12 | 12 | $3,516 | $927.48 | 26.4% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 12 | 15 | $3,510 | $915.29 | 26.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 14 | 14 | $3,192 | $840.28 | 26.3% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 11 | 11 | $2,327 | $575.96 | 24.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 68 | 87 | $3,045 | $556.80 | 18.3% |
| 85610 | Blood test, clotting time | Office | 2023 | 17 | 128 | $1,664 | $537.60 | 32.3% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 25 | 26 | $1,014 | $267.80 | 26.4% |
About Dr. William David, M.D
Dr. William David, M.D is a Cardiovascular Disease healthcare provider based in Lake Mary, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851497242.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William David, M.D has received a total of $68,114 in payments from pharmaceutical and medical device companies, with $2,029 received in 2024. These payments were reported across 518 transactions from 39 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($43,150).
As a Medicare-enrolled provider, David has provided services to 10,855 Medicare beneficiaries, totaling 15,556 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 121 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Lake Mary, FL
- Active Since 09/15/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1851497242
Products in Payments
- ENTRESTO (Drug) $51,320
- Impella (Device) $2,619
- Coronary Orbital Atherectomy System (Device) $1,255
- LEQVIO (Drug) $960.36
- XARELTO (Drug) $849.34
- AVEIR (Device) $799.69
- ELIQUIS (Drug) $635.41
- Barostim Neo System (Device) $416.81
- VERQUVO (Drug) $375.95
- Ensite Cardiac Mapping System (Device) $324.03
- Assurity Pacemaker (Device) $306.96
- Repatha (Biological) $292.64
- MULTAQ (Drug) $215.06
- PRALUENT ALIROCUMAB INJECTION (Biological) $204.10
- Unify Assura CRT Defibrillator (Device) $197.00
- SERELAXIN (Drug) $184.00
- PRADAXA (Drug) $182.48
- BRILINTA (Drug) $166.09
- Corlanor (Drug) $161.21
- NEXLETOL (Drug) $156.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Lake Mary
Dr. Jacob Agamasu, Md, MD
Cardiovascular Disease — Payments: $13,183
Cardiovascular Disease $13,183
Ashraf Jmeian, M.d, M.D
Cardiovascular Disease — Payments: $10,344
Cardiovascular Disease $10,344
Lawrence Vallario, M.d, M.D
Cardiovascular Disease — Payments: $7,458
Cardiovascular Disease $7,458
Dr. Wilberto Lopez, M.d, M.D
Cardiovascular Disease — Payments: $7,281
Cardiovascular Disease $7,281
Jorge Gomez, Md, MD
Cardiovascular Disease — Payments: $4,929
Cardiovascular Disease $4,929